|
|
失代偿性肝硬化合并肾损伤的最新分型与HRS的诊治进展
|
Abstract:
由于失代偿性肝硬化患者特殊的病理生理状况，他们更容易出现肾脏损伤，从而影响其生活质量。类型包括急性肾损伤、急性肾脏病、慢性肾脏病，还包含了一种特殊的急性肾损伤，即肝肾综合征，以肝肾综合征的死亡率最高。近年来，完善并更新了失代偿性肝硬化患者合并肾损伤的相关诊断标准和治疗指南，本文重点阐述了失代偿性肝硬化合并肾损伤的最新临床分型、诊断标准以及肝肾综合征的发病机理、治疗方法，为失代偿肝硬化合并肾损伤的诊断及防治给予理论依据。
Due to the specific pathophysiological condition of patients with decompensated cirrhosis, they are more likely to develop kidney injury, which affects their quality of life. Types include acute kidney injury, acute kidney disease, chronic kidney disease, and also include a specific type of acute kidney injury, namely hepatorenal syndrome, with hepatorenal syndrome having the highest mortality rate. In recent years, relevant diagnostic criteria and treatment guidelines for patients with de-compensated cirrhosis combined with kidney injury have been improved and updated. This article focuses on the latest clinical typology and diagnostic criteria of decompensated cirrhosis combined with kidney injury, as well as the pathogenesis and treatment of hepatorenal syndrome, giving a theoretical basis for the diagnosis and prevention of decompensated cirrhosis combined with kid-ney injury.
| [1] | Ba？ares, R., Nevens, F., Larsen, F.S., et al. (2013) Extracorporeal Albumin Dialysis with the Molecular Adsorbent Recirculating System in Acute-on-Chronic Liver Failure: The Relief Trial. Hepa-tology (Baltimore, Md.), 57, 1153-1162.
https://doi.org/10.1002/hep.26185 |
| [2] | Habas, E., Ibrahim, A.R., Moursi, M.O., et al. (2022) Update on Hepato-renal Syndrome: Definition, Pathogenesis, and Management. Arab Journal of Gastroenterology, 23, 125-133. https://doi.org/10.1016/j.ajg.2022.01.005 |
| [3] | Sanchez, L.O. and Francoz, C. (2021) Global Strategy for the Diag-nosis and Management of Acute Kidney Injury in Patients with Liver Cirrhosis. United European Gastroenterology Journal, 9, 220-228.
https://doi.org/10.1177/2050640620980713 |
| [4] | Francoz, C., Durand, F., Kahn, J.A., et al. (2019) Hepatorenal Syndrome. Clinical Journal of the American Society of Nephrology, 14, 774-781. https://doi.org/10.2215/CJN.12451018 |
| [5] | Gupta, K., Bhurwal, A., Law, C., et al. (2021) Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis. World Journal of Gastroenterology, 27, 3984-4003. https://doi.org/10.3748/wjg.v27.i26.3984 |
| [6] | Ginès, P., Solà, E., Angeli, P., et al. (2018) Hepatorenal Syndrome. Nature Reviews Disease Primers, 4, Article No. 23.
https://doi.org/10.1038/s41572-018-0022-7 |
| [7] | Péron, J.M., Bureau, C., Gonzalez, L., et al. (2005) Treatment of Hepatorenal Syndrome as Defined by the International Ascites Club by Al-bumin and Furosemide Infusion According to the Central Venous Pressure: A Prospective Pilot Study. The American Journal of Gastroenterology, 100, 2702-2707. https://doi.org/10.1111/j.1572-0241.2005.00271.x |
| [8] | Wong, F., Reddy, K.R., O’Leary, J.G., et al. (2019) Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. Liver Trans-plantation, 25, 870-880. https://doi.org/10.1002/lt.25454 |
| [9] | Tonon, M., Rosi, S., Gambino, C.G., et al. (2021) Natural History of Acute Kidney Disease in Patients with Cirrhosis. Journal of Hepatology, 74, 578-583. https://doi.org/10.1016/j.jhep.2020.08.037 |
| [10] | Arroyo, V., Ginès, P., Gerbes, A.L., et al. (1996) Definition and Diagnostic Criteria of Refractory Ascites and Hepatorenal Syndrome in Cirrhosis. Hepatology, 23, 164-176. https://doi.org/10.1002/hep.510230122 |
| [11] | Nadim, M.K., Kellum, J.A., Davenport, A., et al. (2012) Hepatorenal Syndrome: The 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care (London, England), 16, R23.
https://doi.org/10.1186/cc11188 |
| [12] | Kellum, J.A., Lameire, N., Aspelin, P., et al. (2012) Kidney Disease: Im-proving Global Outcome (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International Supplements, 2, 28. |
| [13] | Angeli, P., Ginès, P., Wong, F., et al. (2015) Diagnosis and Management of Acute Kidney Injury in Patients with Cirrhosis: Revised Consensus Recommendations of the Inter-national Club of Ascites. Journal of Hepatology, 62, 968-974.
https://doi.org/10.1016/j.jhep.2014.12.029 |
| [14] | Angeli, P., Garcia-Tsao, G., Nadim, M.K., et al. (2019) News in Pathophysiology, Definition and Classification of Hepatorenal Syndrome: A Step beyond the International Club of Asci-tes (ICA) Consensus Document. Journal of Hepatology, 71, 811-822. https://doi.org/10.1016/j.jhep.2019.07.002 |
| [15] | Flamm, S.L., Wong, F., Ahn, J., et al. (2022) AGA Clinical Prac-tice Update on the Evaluation and Management of Acute Kidney Injury in Patients with Cirrhosis: Expert Review. Clini-cal Gastroenterology and Hepatology, 20, 2707-2716.
https://doi.org/10.1016/j.cgh.2022.08.033 |
| [16] | Khwaja, A. (2012) KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clinical Practice, 120, c179-c184. https://doi.org/10.1159/000339789 |
| [17] | Piano, S., Rosi, S., Maresio, G., et al. (2013) Evaluation of the Acute Kidney Injury Network Criteria in Hospitalized Patients with Cir-rhosis and Ascites. Journal of Hepatology, 59, 482-489. https://doi.org/10.1016/j.jhep.2013.03.039 |
| [18] | Biggins, S.W., Angeli, P., Garcia-Tsao, G., et al. (2021) Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacte-rial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 74, 1014-1048. https://doi.org/10.1002/hep.31884 |
| [19] | Juanola, A., Solé, C., Toapanta, D., et al. (2021) Monitoring Renal Function and Therapy of Hepatorenal Syndrome Patients with Cirrhosis. Clinics in Liver Disease, 25, 441-460. https://doi.org/10.1016/j.cld.2021.01.011 |
| [20] | Kazory, A. and Ronco, C. (2019) Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data. Cardiorenal Medicine, 9, 1-7. https://doi.org/10.1159/000492791 |
| [21] | Trebicka, J., Amoros, A., Pitarch, C., et al. (2019) Addressing Pro-files of Systemic Inflammation across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. Frontiers in Immunology, 10, 476.
https://doi.org/10.3389/fimmu.2019.00476 |
| [22] | Hasan, I., Rashid, T., Chirila, R.M., et al. (2021) Hepatorenal Syndrome: Pathophysiology and Evidence-Based Management Update. Romanian Journal of Internal Medicine, 59, 227-261. https://doi.org/10.2478/rjim-2021-0006 |
| [23] | Solé, C., Solà, E., Huelin, P., et al. (2019) Characterization of Inflammatory Response in Hepatorenal Syndrome: Relationship with Kidney Outcome and Survival. Liver Interna-tional, 39, 1246-1255. https://doi.org/10.1111/liv.14037 |
| [24] | Chancharoenthana, W. and Leelahavanichkul, A. (2019) Acute Kidney Injury Spectrum in Patients with Chronic Liver Disease: Where Do We Stand? World Journal of Gastroenterology, 25, 3684-3703.
https://doi.org/10.3748/wjg.v25.i28.3684 |
| [25] | Csak, T. and Bernstein, D. (2022) Hepatorenal Syndrome: Patho-physiology. Clinics in Liver Disease, 26, 165-179.
https://doi.org/10.1016/j.cld.2022.01.013 |
| [26] | Fickert, P. and Rosenkranz, A.R. (2020) Cholemic Nephropathy Reloaded. Seminars in Liver Disease, 40, 91-100.
https://doi.org/10.1055/s-0039-1698826 |
| [27] | Tinti, F., Umbro, I., D’Alessandro, M., et al. (2021) Cholemic Nephropathy as Cause of Acute and Chronic Kidney Disease. Update on an Under-Diagnosed Disease. Life (Basel, Switzerland), 11, 1200.
https://doi.org/10.3390/life11111200 |
| [28] | Liu, J., Qu, J., Chen, H., et al. (2021) The Pathogenesis of Renal Injury in Obstructive Jaundice: A Review of Underlying Mechanisms, Inducible Agents and Therapeutic Strategies. Pharma-cological Research, 163, Article ID: 105311.
https://doi.org/10.1016/j.phrs.2020.105311 |
| [29] | Simonetto, D.A., Gines, P. and Kamath, P.S. (2020) Hepatorenal Syndrome: Pathophysiology, Diagnosis, and Management. BMJ, 370, m2687. https://doi.org/10.1136/bmj.m2687 |
| [30] | FDA Announcement (2022) FDA Approves Treatment to Improve Kidney Function in Adults with Hepatorenal Syndrome.
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-improve-kidney-function-adults-hepatorenal-syndrome |
| [31] | Clinical Trails.gov. (2022) Study to Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1. https://www.clinicaltrials.gov/ct2/show/NCT02770716 |
| [32] | FDA Approved (2022) Terlipressin Label and Prescribing Information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022231s000lbl.pdf |
| [33] | El-Desoki Mahmoud, E.I., Abdelaziz, D.H., Abd-Elsalam, S., et al. (2021) Norepinephrine Is More Effective than Midodrine/Octreotide in Patients with Hepatorenal Syndrome-Acute Kidney Injury: A Randomized Controlled Trial. Frontiers in Pharmacology, 12, Arti-cle ID: 675948. https://doi.org/10.3389/fphar.2021.675948 |
| [34] | Subedi, A., Kumar, V.C.S., Subedi, A.S., et al. (2021) A Review of Hepatorenal Syndrome. Cureus, 13, e16084.
https://doi.org/10.7759/cureus.16084 |
| [35] | Buccheri, S., Da, B.L. (2022) Hepatorenal Syndrome: Definitions, Di-agnosis, and Management. Clinics in Liver Disease, 26, 181-201. https://doi.org/10.1016/j.cld.2022.01.002 |
| [36] | Lavayssiere, L., Kallab, S., Cardeau-Desangles, I., et al. (2013) Im-pact of Molecular Adsorbent Recirculating System on Renal Recovery in Type-1 Hepatorenal Syndrome Patients with Chronic Liver Failure. Journal of Gastroenterology and Hepatology, 28, 1019-1024. https://doi.org/10.1111/jgh.12159 |
